Palatin Technologies (PTN) Total Non-Current Liabilities (2015 - 2024)
Palatin Technologies' (PTN) quarterly Total Non-Current Liabilities came in at $10.0 million in Q3 2024, down 29.17% on a YoY basis from $14.1 million in Q4 2023, and down 7.92% quarter-over-quarter from $10.9 million in Q2 2024.
Analysis
Palatin Technologies (PTN) Total Non-Current Liabilities (2015 - 2024) Analysis & Trends
Palatin Technologies (PTN) has reported Total Non-Current Liabilities for 10 consecutive years, with $10.0 million the latest figure, recorded in Q3 2024.
- For the quarter ending Q3 2024, Total Non-Current Liabilities fell 29.17% year-over-year to $10.0 million; the trailing twelve-month figure through Sep 2024 stood at $10.0 million (down 29.17% YoY), and the FY2024 full-year result was $10.9 million, down 39.04% from the prior year.
- Total Non-Current Liabilities fell to $10.0 million in Q3 2024 per PTN's latest filing, from $10.9 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $17.8 million in Q2 2023 and bottomed at $3.4 million in Q1 2020.
- Historically, Total Non-Current Liabilities has averaged $11.7 million across 5 years, with a median of $11.9 million in 2022.
- The sharpest annual moves came in 2020 and 2024: Total Non-Current Liabilities soared 489.5% in 2020, then plunged 39.04% in 2024.
- Over 5 years, Total Non-Current Liabilities stood at $8.1 million in 2020, then jumped by 82.41% to $14.8 million in 2021, then decreased by 19.51% to $11.9 million in 2022, then increased by 6.42% to $12.7 million in 2023, then fell by 21.08% to $10.0 million in 2024.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $10.0 million, $10.9 million, and $8.8 million for Q3 2024, Q2 2024, and Q1 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 81.11 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 36.04 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 5.92 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 7.74 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 40.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 3.92 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 12.42 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 378.37 Mn |
| 10 | Palatin Technologies | 46.98 Mn | 46.98 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | 9.99 Mn |
| Jun 30, 2024 | 10.85 Mn |
| Mar 31, 2024 | 8.80 Mn |
| Dec 31, 2023 | 12.66 Mn |
| Sep 30, 2023 | 14.11 Mn |
| Jun 30, 2023 | 17.81 Mn |
| Mar 31, 2023 | 12.24 Mn |
| Dec 31, 2022 | 11.90 Mn |
| Sep 30, 2022 | 16.45 Mn |
| Jun 30, 2022 | 16.94 Mn |
| Mar 31, 2022 | 12.74 Mn |
| Dec 31, 2021 | 14.78 Mn |
| Sep 30, 2021 | 10.60 Mn |
| Jun 30, 2021 | 11.41 Mn |
| Mar 31, 2021 | 11.02 Mn |
| Dec 31, 2020 | 8.11 Mn |
| Sep 30, 2020 | 13.56 Mn |
| Jun 30, 2020 | 4.88 Mn |
| Mar 31, 2020 | 3.36 Mn |
| Dec 31, 2019 | 1.37 Mn |